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Background. Long-term survivors of vertically acquired human immunodeﬁciency virus (HIV) infection are
reaching adolescence in large numbers in Africa and are at high risk of delayed diagnosis and chronic compli-
cations of untreated HIV infection. Chronic respiratory symptoms are more common than would be anticipated
based on the HIV literature.
Methods. Consecutive adolescents with presumed vertically acquired HIV attending 2 HIV care clinics in
Harare, Zimbabwe, were recruited and assessed with clinical history and examination, CD4 count, pulmonary
function tests, Doppler echocardiography, and chest radiography (CXR). Those with suspected nontuberculous
chronic lung disease (CLD) were scanned using high-resolution computed tomography (HRCT).
Results. Of 116 participants (43% male; mean age, 14± 2.6 years, mean age at HIV diagnosis, 12 years), 69%
were receiving antiretroviral therapy. Chronic cough and reduced exercise tolerance were reported by 66% and
21% of participants, respectively; 41% reported multiple respiratory tract infections in the previous year, and 10%
were clubbed. More than 40% had hypoxemia at rest (13%) or on exercise (29%), with pulmonary hypertension
(mean pulmonary artery pressure >25 mm Hg) in 7%. Forced expiratory volume in 1 second (FEV1) was <80%
predicted in 45%, and 47% had subtle CXR abnormalities. The predominant HRCT pattern was decreased attenu-
ation as part of a mosaic attenuation pattern (31 of 56 [55%]), consistent with small airway disease and associated
with bronchiectasis (Spearman correlation coefﬁcient (r
2= 0.8) and reduced FEV1 (r
2 =−0.26).
Conclusions. Long-term survivors of vertically acquired HIV in Africa are at high risk of a previously unde-
scribed small airway disease, with >40% of unselected adolescent clinic attendees meeting criteria for severe hypoxic
CLD. This condition is not obvious at rest. Etiology, prognosis, and response to treatment are currently unknown.
More than 90% of the estimated 2 million global pedi-
atric human immunodeﬁciency virus (HIV) infections
occur in sub-Saharan Africa, predominantly due to
mother-to-child transmission [1]. Although untreated
HIV infection in infants is associated with a high risk
of rapid disease progression [2], up to one-third of
HIV-infected infants are “slow progressors,” with an
estimated median survival of a decade or more [3–5].
Two percent to 3% of all 10-year-olds living in
Southern Africa may be HIV-infected long-term
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mated burdens reﬂect high regional HIV prevalence rates in
pregnant women during the 1990s and lack of interventions to
prevent mother-to-child transmission at that time.
Clinicians in sub-Saharan Africa have become familiar with
the clinical manifestations of untreated slow progressors, who
typically present in later childhood with pronounced stunting,
severe immunosuppression, or chronic complications of un-
treated HIV [6]. The best-documented regional epidemic is in
Zimbabwe, where 43% of 25000 children attending HIV care
clinics in 2008 were aged ≥10 years [7]. Recently diagnosed or
still undiagnosed vertically acquired HIV is now the most
common cause of admission to the hospital and the most
common cause of in-hospital deaths among adolescents in the
region [8]. Undocumented epidemics of similar magnitude are
thought to affect neighboring countries.
The natural history of HIV infection in older children is
less well deﬁned than for infants or adults. Presentation with
chronic cough is common and often leads to presumptive
treatment for unconﬁrmed tuberculosis. Respiratory illness,
frequently with a history suggestive of acute-on-chronic lung
disease, was the most common cause of death among HIV-
infected adolescents admitted to a hospital in Harare [8].
Among younger children, the most common cause of chronic
lung disease (CLD) is lymphocytic interstitial pneumonitis
(LIP), found in 30%–40% of HIV-infected untreated
children [9]. LIP is associated with a slower progression of
HIV infection and responds well to antiretroviral therapy
(ART) [9, 10]. The cause of HIV-related CLD in older chil-
dren and adolescents has not previously been investigated.
The aim of this study was to investigate the clinical features
and morphologic characteristics of CLD in older children with
vertically acquired HIV infection attending HIV care outpatient
services in 2 public-sector hospitals in Harare, Zimbabwe.
METHODS
Study Participants
Consecutive patients aged 10–19 years attending 2 HIV care
outpatient clinics at Parirenyatwa Hospital and Harare Central
Hospital (Harare, Zimbabwe) were enrolled (maximum 8 per
day for logistic ease). Exclusion criteria were horizontally ac-
quired HIV infection, pregnancy, being too ill to participate
(requiring immediate hospitalization), living outside Harare,
and having pulmonary Kaposi sarcoma, recently diagnosed
smear-positive tuberculosis, or acute respiratory tract infection.
Clinical Data Collection
Interview data recorded the reasons for HIV testing, duration
of ART, respiratory symptoms, and exercise tolerance
(New York Heart Association [NYHA] scale [11]). Standard
respiratory examination and anthropometric assessment,
including height, weight, and Tanner staging, were performed.
All participants underwent CD4 count measurement (CyFlow
counter, Partec GmbH), spirometry, Doppler echocardiogra-
phy, and chest radiography (CXR); high-resolution computed
tomography (HRCT) was performed if CLD was suspected.
The World Health Organization (WHO) Adult Classiﬁcation
was used to stage HIV infection [12]. HIV infection was pre-
sumed to be vertically acquired if the following case deﬁnition
was met: maternal and/or sibling death or known maternal
HIV infection, plus no history of sexual debut or blood trans-
fusion, and at least 2 of the following: frequent infections
during early childhood, stunting, or pubertal delay [6].
Pulmonary Function Tests
Oxygen saturation (O2 sat) and respiratory rate were measured
at rest and after exercise (a 200-m brisk walk). Participants
with a respiratory rate >25 breaths/minute or O2 sat <92% at
rest were not exercised.
Spirometry was performed using a Microloop spirometer
(Mk8, MicroMedical). Participants were actively encouraged
during the maneuver verbally and with pictorial incentives to
blow out maximally. A nose clip was used; 3 reproducible,
technically adequate measurements were taken in the standing
position, and the maximal values were recorded. At least 30
seconds were allowed between each maneuver.
Laboratory Investigations
Participants with cough of any duration were asked to provide
2 sputum specimens. Bacterial pathogens were identiﬁed using
standard techniques [13]. Concentrated decontaminated
sputum specimens were examined using Auramine and Ziehl-
Neelsen staining and cultured on Lowenstein-Jensen media,
with positive mycobacterial cultures conﬁrmed by genotyping
using the Hain assay (Hain LifeScience GmbH).
Radiologic Data
Participants with clinically suspected CLD or CXR abnormal-
ity (assessed locally) were invited to undergo HRCT scanning
(Siemens Emotion 6). Those with suspected active mycobac-
terial disease were excluded. In separate sessions, CXR and
HRCT scans were scored independently by 2 thoracic radiol-
ogists blinded to clinical data. CXR abnormalities were quanti-
ﬁed using a previously developed scoring system [14]. HRCT
abnormalities were categorized on the basis of patterns reﬂect-
ing either airway pathology or parenchymal disease using
standard deﬁnitions (see Supplementary Data) [15].
Statistical Analysis
The z scores for height-for-age and weight-for-age were calcu-
lated using British Growth Reference Curves [16]. Scores of
≤2 were considered to represent stunting and wasting,
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using age-, sex-, and height-adjusted standards in healthy Ma-
lawian schoolchildren [17]. Quantitative interrelationships
were examined using Spearman rank correlation coefﬁcient:
HRCT lobar scores were summed to provide global HRCT
scores for speciﬁc variables. Interobserver variation for HRCT
and CXR abnormalities with a prevalence of ≥15% was exam-
ined using the kappa (κ) coefﬁcient of agreement.
Clinical Case Deﬁnitions
Acute Respiratory Tract Infection
Acute onset of respiratory tract infection (<2 weeks) was
deﬁned as the presence of ≥2 of the following: fever, cough,
purulent sputum, and clinical response to antibiotics (amoxi-
cillin and/or erythromycin).
Tuberculosis
Deﬁnite tuberculosis was deﬁned as a positive, genotype-
conﬁrmed culture for Mycobacterium tuberculosis; probable
active mycobacterial disease was deﬁned as 2 sputum smears
positive for acid-fast bacilli on Ziehl-Neelsen staining without
culture conﬁrmation.
Clinically Suspected CLD
CLD was deﬁned as at two or more of chronic cough (present
most days for 3 months of the year in the past 2 years), recur-
rent respiratory tract infections (> antibiotic courses in the last
year) and moderate to severe limitation in physical activity
caused by breathlessness (NYHA class 2–4), and/or an existing
diagnosis and/or signs of cor pulmonale (ﬁnger clubbing,
raised jugular venous pressure), or hypoxia (O2 sat ≥92%) at
rest, or desaturation (O2 sat ≥5%) on exercise.
Ethical Considerations
Written informed consent was obtained from all participants
and from guardians of participants aged <16 years. Ethical
approval was obtained from the Medical Research Council of
Zimbabwe, the London School of Hygiene and Tropical Medi-
cine Ethics Committee, and the Biomedical Research and
Training Institute Institutional Review Board.
RESULTS
Demographic and Clinical Characteristics
Five individuals were excluded (1 with a recent diagnosis of
tuberculosis, 3 who did not obtain parental consent, and 1
with likely horizontallyacquired HIV infection). Characteristics
of the 116 participants (mean age, 14± 2.6 years, 43% male)
are summarized in Table 1. None were cigarette smokers or had
smoke exposure from indoor open ﬁres. HIV was diagnosed a
median of 23 months (interquartile range [IQR], 10–45) before
recruitment, and 99 patients (85%) had WHO stage 3/4
disease. Reasons for HIV testing were presumed tuberculosis
in 20 (17%), repeated chest infections or coughing in 23 (20%),
other illnesses in 60 (52%), and following HIV diagnosis in a
parent or parental death in 13 (11%). Eighty (69%) partici-
pants were taking ART for a median duration of 20 months
(IQR, 5–40). Overall, median CD4 count was 384 cells/µL
(IQR, 180–584) and did not differ between those who were
receiving ART (median CD4 count, 402 cells/µL) and those
who were not (median CD4 count, 351 cells/µL) (P<.58).
Eighty-two (71%) participants had a prior diagnosis of
CLD made by a physician, and 42 (36%) had been treated for
suspected tuberculosis at least once. Disabling respiratory
insufﬁciency was common (Table 2): 24 (21%) reported
reduced exercise tolerance (NYHA class >2), 41 (35%) were
dyspneic at rest and/or hypoxic at rest, and 21 (29%) had a
≥5% fall in O2 sat following exercise. Abnormal lung function
(forced expiratory volume in 1 second [FEV1] <80% pre-
dicted) was noted in 52 (45%) participants. Of ART-naive
participants with CD4 counts >350 cells/µL, 8 of 18 (44%)
Table 1. Baseline Demographic and Clinical Characteristics of
Study Participants (N=116)
Baseline Characteristic No. (%)
Age, years
≤12 34 (29)
13–15 39 (34)
16–18 43 (37)
Male 50 (43)
Orphanhood
Both parents alive 9 (8)
Single orphan 51 (44)
Double orphan 56 (48)
Educational level
None 3 (2)
Primary 52 (45)
Secondary 61 (53)
Age at HIV diagnosis, y, median (IQR) 12 (10–15)
Taking co-trimoxazole prophylaxis 111 (96)
Taking ART 80 (69)
Type of ART
2 NRTI+1 NNRTI 72 (62)
2 NRTI+PI 6 (5)
Height-for-age z score, median (IQR) −1.96 (−2.9 to −1.3)
Weight-for-age z score, median (IQR) −1.74 (−2.9 to −0.79)
BMI z score, median (IQR) −0.69 (−1.7 to 0.1)
Pubertal delay (Tanner stage 1/2 in ≥14 y)
a 21 (18)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human
immunodeficiency virus; IQR, interquartile range; NNRTI, nonnucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor.
a Data missing for 2 participants.
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mal HRCT scan. There was no association between FEV1 and
duration of ART or current CD4 count (P=.65 and P=.31,
respectively). On Doppler echocardiography, 16 patients
(14%) had raised mean pulmonary artery pressure >20 mm
Hg and 7% had pulmonary hypertension (mean pulmonary
artery pressure >25 mm Hg) [18].
Microbiologic Findings
Sputum, obtained from 54 (46%) participants, was culture
positive for bacteria/fungi in 18 (33%): Haemophilus inﬂuen-
zae (n =6), Staphylococcus aureus (n =5), Moraxella catarrha-
lis (n= 5), Pseudomonas aeruginosa (n =3), Streptococcus
pneumoniae (n =2), Klebsiella pneumoniae (n =1), Listeria
monocytogenes (n =1), and Candida albicans (n =3). Myco-
bacterial cultures were positive in 12 patients: M. tuberculosis
was grown from 8 participants (smear positive= 7); addition-
ally, 31 (27%) participants had organisms seen on sputum
microscopy (staining on both auramine-O and Ziehl-Neelsen
stains, but negative culture results from specimens taken at
recruitment). Of these, Mycobacterium gordonae was cultured
from 4 (3%) participants, and 18 (16%) had conﬁrmation of
positive microscopy but negative cultures when repeat sputum
specimens were taken before commencement of antitubercu-
lous treatment and processed in a second independent myco-
bacterial culture laboratory. Unprocessed sputum specimens
were sent to the second laboratory because of the unexpectedly
high prevalence of smear positivity and concern about
possible laboratory artifact (morphology was reported to be
unusual for M. tuberculosis) or a nosocomial epidemic of
M. tuberculosis.
Radiologic Findings
Abnormalities on chest radiography were reported in 55 partici-
pants (47%), the most common being ring and tramline opaci-
ties. Features of posttuberculous lung disease (such as volume
loss and ﬁbrosis) were not prominent, despite the high pro-
portion of participants who had been treated for tuberculosis.
One hundred participants (86%) met study case deﬁnitions
for suspected CLD (see the “Methods” section), of whom 56
(56%) had HRCT performed: the investigation was withheld
in 23 because of positive sputum microscopy infection control
hazard, and an additional 21 participants were referred but
did not attend, including 1 who had died. The median interval
between CXR and HRCT in the remaining 56 participants was
2 months. Interobserver agreement was good for presence of
speciﬁc HRCT abnormalities (bronchiectasis, κ=0.74; bron-
chial wall thickening, κ=0.70; small airway (centrilobular)
Table 2. Respiratory Symptoms and Signs in Study Participants
Characteristic Patients, No. (%)
Clinical history
Previously treated for tuberculosis
a 42 (36)
History of other cardiorespiratory conditions
Treatment for asthma 11 (9)
Treatment for PCP 7 (6)
Dilated cardiomyopathy 1 (1)
Hospitalized for LRTI in the past year 19 (16)
>2 courses of antibiotics for LRTI in the past year 48 (41)
Recurrent
b cough±purulent sputum 77 (66)
NYHA class
c
1 72 (62)
2 20 (17)
3 22 (19)
4 2 (2)
Symptoms (current/recent)
Cough 84 (72)
Sputum 54 (47)
Exertional chest tightness 49 (42)
Clinical assessment
Clubbing 12 (10)
Bibasal crackles 37 (32)
Wheeze on auscultation 2 (2)
Tachycardia (HR >100), at rest 35 (30)
Respiratory rate >25/min at rest 33 (28)
Resting O2 sat <92% at rest 15 (13)
Drop of ≥5% O2 sat on exercise testing (n=72)
d 21 (29)
Pulmonary arterial pressure (n=110)
e
<20 mm Hg 94 (86)
20–25 mm Hg 8 (7)
>25 mm Hg 8 (7)
FEV1, % predicted
80–100 64 (55)
50–79 40 (35)
<50 12 (10)
PEFR, % predicted
80–100 83 (72)
50–79 28 (24)
<50 5 (4)
Abbreviations: FEV1, forced expiratory volume in 1 second; HR, heart rate;
LRTI, lower respiratory tract infection; NYHA, New York Heart Association;
PCP, pneumocystis pneumonia; PEFR, peak expiratory flow rate.
a Three participants treated twice.
b Most days in at least 3 mo in the year in past 2 years.
c NYHA functional classification:1 =no symptoms and no limitation in
physical activity; 2= mild symptoms and slight limitation during physical
activity; 3= marked limitation of activity due to symptoms; 4 =severe
limitations in activity, symptoms at rest.
d Three not mobile; 26 had respiratory rate >25; 7 had O2 sat <92% and
RR>25; 8 had O2 sat <92%.
e Measured on Doppler echocardiography.
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ation, κ=0.75; noncavitating nodules, κ= 0.57).
CXR and HRCT Abnormalities in Participants Meeting
Case Deﬁnition for CLD
Radiologic ﬁndings in the 56 participants who received HRCT
scans are summarized in Table 3. Of note, the prevalence of
CXR abnormalities was not signiﬁcantly different between
participants meeting case deﬁnitions for CLD who received
HRCT scans and those who met case deﬁnitions but did not
undergo HRCT (data not shown). Decreased attenuation con-
sistent with small airway disease was the most common and
most extensive HRCT abnormality, followed by (and associ-
ated with) large airway abnormalities (bronchial wall thicken-
ing, small and large airway plugging, and bronchiectasis;
Figure 1, Table 3). Our protocol obtained HRCT images at full
inspiration (having not anticipated the high prevalence of
small airway disease), but pronounced decreased attenuation
was observed in 4 HRCT scans serendipitously performed in
the expiratory phase. Ground-glass opaciﬁcation and nodules
were seen in a minority of cases, and features suggesting inter-
stitial lung disease were also rare.
On HRCT, the extent of decreased attenuation was strongly
correlated with extent of bronchiectasis (Spearman correlation
Table 3. Prevalence of Abnormalities on Chest Radiography
and High-Resolution Computed Tomography in 56 Patients Under-
going Full Imaging Evaluation
Radiologic Abnormality
Prevalence of
Abnormality,
No. (%)
With >5% Extent
of Abnormality,
No. (%)
CXR
Rings/tramline
opacities
18 (32) 18 (32)
Consolidation 7 (12) 6 (11)
Volume loss 7 (12) NA
Paucity of vascular
markings
5 (9) NA
Noncavitating
nodules
4 (7) 4 (7)
Ground-glass
opacification
2 (4) 2 (4)
Hyperexpansion 2 (4) NA
Reticular pattern 0 (0) 0 (0)
HRCT
Airway abnormality
Decreased
attenuation
31 (55) 27 (48)
Bronchiectasis 24 (43) NA
Bronchial wall
thickening
20 (36) NA
Small airway
plugging
13 (23) NA
Large airway
plugging
6 (11) NA
Parenchymal
abnormality
Consolidation 18 (32) 4 (7)
Noncavitating
nodules
11 (20) 2 (4)
Reticular pattern 1 (2) 0 (0)
Emphysema 8 (14) 1 (2)
Cysts 6 (11) 3 (5)
Ground-glass
opacification
6 (11) 1
a (2)
Cavitation 3 (5) 0 (0)
Abbreviation: CXR, chest radiography; HRCT, high-resolution computed
tomography; NA, not applicable.
a 90% extent.
Figure 1. Lung high-resolution computed tomography ﬁndings in par-
ticipants. A, Image section at the level of the carina in a 15-year-old
female. There is a clear zone of decreased attenuation in the right upper
lobe (and, to a lesser extent, the left lung). In regions of decreased
attenuation there is reduction in the caliber of pulmonary vessels; there
was no bronchiectasis in this patient. B, Image section in a 19-year-old
male through the lower zones demonstrating focal areas of decreased
attenuation in both lungs (arrows) and bronchiectasis in the left lower
lobe (arrowheads).
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ing large airway pathology (severity of bronchial wall dilata-
tion (rs= 0.80; P< .001) and bronchial wall thickening (rs=
0.73; P< .001). The association between extent of decreased
attenuation and a composite score of the extent of small and
large airway plugging on HRCT (“secretion score”)w a s
weaker but statistically signiﬁcant (rs=0.48; P<.001). The
extent of bronchiectasis was also signiﬁcantly associated with
secretion score (rs=0.60; P< .001). Ring/tramline opacities on
CXR were associated with secretion score (P=.006) but not
with any other HRCT abnormalities, including decreased
attenuation, bronchiectasis, bronchial wall thickening, or
bronchial dilatation. Consolidation on CXR was also signiﬁ-
cantly correlated with HRCT secretion score (P= .005).
Association Between HRCT Patterns and FEV1
The extent of decreased attenuation was inversely correlated
with FEV1 (rs= −0.26; P= .06), as was consolidation (rs=
−0.3; P= .05). No other HRCT features, including bronchiec-
tasis, correlated with FEV1.
DISCUSSION
The major ﬁnding of this study was the high burden of severe
respiratory insufﬁciency among HIV-infected older children
receiving HIV care after delayed diagnosis of presumed verti-
cally acquired HIV infection. Two-thirds had chronic cough;
recurrent lower respiratory tract infections and active myco-
bacterial disease were common, including persistent culture-
negative smear positivity potentially reﬂecting nontuberculous
mycobacterial disease. Pulmonary function tests were abnor-
mal in 45% of participants, and a similar proportion had
resting or exertional hypoxia. Pulmonary arterial hypertension
was present in 7%. HRCT suggested small airway disease as
the predominant underlying pathology, a previously unde-
scribed ﬁnding with major implications for the health and
long-term survival of perinatally HIV-infected adolescents.
We had anticipated a high prevalence of LIP in our cohort
because it is the most common cause of HIV-associated CLD
in younger children and because slow HIV progression and
LIP are strongly correlated [9, 10, 19]. However, there was a
striking absence of features (cysts and ground-glass opaciﬁca-
tion) to support active LIP or subsequent ﬁbrosis [20]. This
may reﬂect the natural history of LIP for self-resolution and
prompt response to ART [21]. Instead, the most prevalent
abnormality on HRCT was patchy (mosaic) decreased attenu-
ation, for which the differential diagnosis is small airway
disease, chronic pulmonary thromboembolic lung disease, or
inﬁltrative lung disease. Of these, small airway disease is by far
the most likely because of the signiﬁcant association with (1)
FEV1 (an index of airﬂow limitation) and (2) large airway
abnormalities such as bronchiectasis.
The most common small airway disease is asthma, but the
relatively stable clinical condition of hypoxic participants (at-
tending a routine outpatient clinic and not in acute distress
when recruited) argues against this diagnosis, as does the low
prevalence of wheezing. Moreover, we have since conﬁrmed a
similarly high prevalence of hypoxic lung disease and shown
lack of responsiveness to inhaled bronchodilators (excluding
asthma) among older children and adolescents receiving HIV
care in Blantyre, Malawi [22]. This leaves obliterative bron-
chiolitis as the most common cause of CLD in this patient
group [23, 24].
Obliterative bronchiolitis is a life-threatening condition that
responds poorly to treatment. It can progress to hypoxic res-
piratory failure and cor pulmonale or it can develop acutely
and then remain at a relatively stable level of disability (eg,
when due to adenovirus infection). In young children it may
impair subsequent lung development. Obliterative bronchioli-
tis can result from a number of insults, including drug reac-
tions; inhalation of allergens or toxins; and infection with a
number of pathogens including adenovirus, mycoplasma, res-
piratory syncytial virus, or inﬂuenza, It is also an integral
feature of the pathology of cystic ﬁbrosis and chronic rejection
following lung transplantation, with some evidence for genetic
predisposition to severe forms [25]. It is thought to result
from epithelial injury in the small airways, which undergo
repair with ﬁbrosis, leading to narrowing and airﬂow limit-
ation [26]. Obliterative bronchiolitis has not been recognized
in European or American cohorts of HIV-infected children,
suggesting either geographic variability (eg, infantile adeno-
viral obliterative bronchiolitis has a Southern hemisphere
predominance) or that ART during early childhood is pre-
ventive [27].
Obliterative bronchiolitis is prone to misdiagnosis and diag-
nostic delay because patients often appear well at rest with
only subtle clinical and plain radiologic abnormalities [28]. In
our study, the main HRCT ﬁnding had no CXR correlate,
except in the subgroup with concurrent bronchiectasis.
Decreased attenuation on HRCT was reported from lobes
without overt bronchiectasis, implying that small airway
disease precedes development of bronchiectasis [29], a
phenomenon well recognized in obliterative bronchiolitis due
to cystic ﬁbrosis and adenovirus infection [25, 30].
HIV has not previously been recognized as predisposing to
childhood obliterative bronchiolitis , but untreated HIV-
infected children frequently experience multiple bacterial and
viral respiratory tract infections over many years [6]. We pos-
tulate that these infections, together with HIV-induced
impairment of innate immune responses [31, 32], predispose
to chronic lower respiratory tract inﬂammation that in turn
150 ￿ CID 2012:55 (1 July) ￿ Ferrand et alincreases susceptibility to further respiratory tract infections.
Small airway disease may then result from cumulative inﬂam-
matory damage incurred during unusually frequent or severe
viral/bacterial infections (similar to HIV-negative children
with adenovirus, measles, or Bordetella infection). Alterna-
tively, HIV-infected children may be predisposed to an
inﬂammatory obliterative bronchiolitis that does not require a
secondary pathogen other than HIV itself. In either event,
host pulmonary inﬂammatory responses may be modulated
by HIV and potentially by genetically determined immunolo-
gic responses. Persistent airway inﬂammation facilitates airway
remodeling and development of bronchiectasis [33–36].
Previous studies of HIV-related CLD in this age group are
limited to CXR ﬁndings [9, 37, 38], which are insensitive and
subject to observer error and inconsistent use of termino-
logy [39]. The strengths of this study are its prospective
design, unselected recruitment, exclusion of acutely unwell
patients, use of HRCT, and low interobserver variability in
CXR and HRCT scoring. Limitations include the cross-sec-
tional design, incomplete uptake of HRCT in participants
meeting deﬁnitions for chronic lung disease, and lack of histo-
logic conﬁrmation. Although histology provides the “gold
standard” for diagnosis of obliterative bronchiolitis, open or
thorascopic lung biopsy or postmortem examination is re-
quired because of the patchy and peripheral nature of the
disease process [40]. Increasingly, HRCT without biopsy is
considered to be sufﬁciently characteristic to be used for
initial diagnosis, and the chronic symptoms, structural
damage, mosaic pattern of decreased attenuation, and strong
association with FEV1 provide strong evidence for obliterative
bronchiolitis in our patients [41]. Finally, although we were
careful to avoid further selection bias, our recruitment was
limited to adolescents known to be receiving HIV care ser-
vices, whereas the majority of African adolescent survivors of
perinatal HIV infection are still undiagnosed [7].
Our study showed a substantial burden of CLD in vertically
HIV-infected adolescents, even at high CD4 counts and fol-
lowing several years of ART. Other than a single case report in
an HIV-infected 11-year-old, this is the ﬁrst description of
small airway disease as a cause of HIV-associated CLD [42].
As HIV epidemics mature, increasing numbers of previously
undiagnosed HIV-infected older children are being identi-
ﬁed [6]. Our ﬁndings suggest that HIV-infected children with
chronic respiratory symptoms or evidence of airﬂow obstruc-
tion should be investigated for possible obliterative bronchioli-
tis as well as for mycobacterial disease. Earlier diagnosis of
HIV infection may be crucial to preventing the development
of CLD and suggests that international recommendations
(which currently do not support immediate initiation of ART
in children diagnosed over the age of 2 years) need to take the
high risk of CLD and potential for prevention with early ART
initiation into account. The lack of association between CD4
count or duration of ART and pulmonary function infers that
once established, lung damage may be irreversible. Possible
intervention strategies include aggressive management of in-
tercurrent infection and use of prophylactic antibiotics, which
may delay progression of airway disease and reduce morbidity,
and, potentially, corticosteroids [43]. Further investigation of
the natural history, histopathology, geographic distribution,
pathogenesis, and management of this newly described and
highly prevalent HIV-associated CLD is needed.
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